$175.00
Looking to buy Semaglutide for your research? Our lab-verified >98% pure Semaglutide peptide is trusted by researchers worldwide for metabolic, glycemic control, and obesity research studies. In stock – ready to ship within 24 hours.
✅ Lab-Tested >98% Purity (COA Included)
✅ GLP-1 Receptor Agonist
✅ Oral & Subcutaneous Research Applications
✅ Fast, Discreet Shipping Worldwide
✅ Trusted by Leading Research Institutions
Semaglutide is a 31-amino-acid peptide engineered to mimic the endogenous incretin hormone glucagon-like peptide-1 (GLP-1). As a GLP-1 receptor agonist, it binds to and activates GLP-1 receptors, stimulating glucose-dependent insulin secretion, suppressing inappropriate glucagon release, and slowing gastric emptying .
When you buy Semaglutide from Mega Protide, you’re getting a research-grade peptide that has been third-party tested for purity and potency. This Semaglutide research peptide is widely used in metabolic, glycemic control, and obesity research.
| Parameter | Details |
|---|---|
| Type | 31-amino-acid peptide |
| Receptor Target | GLP-1 Receptor Agonist |
| Molecular Formula | C₁₈₇H₂₉₁N₄₅O₅₉ |
| Molecular Weight | ~4113.6 g/mol |
| CAS Number | 910463-68-2 |
| Form | Lyophilized powder |
| Quantity | 5mg or 10mg per vial |
| Purity | >98% by HPLC |
| Storage | Refrigerate at 2-8°C after reconstitution |
| Route | Subcutaneous injection or oral research applications |
Semaglutide exerts its effects through three primary pathways :
| Mechanism | Effect |
|---|---|
| Insulin Secretion | Activates GLP-1 receptors on pancreatic beta-cells, enhancing insulin release only when blood glucose is elevated |
| Glucagon Suppression | Inhibits glucagon release from pancreatic alpha-cells, preventing excess hepatic glucose production |
| Gastric Emptying | Slows the rate of gastric emptying, promoting prolonged satiety and reducing caloric intake |
| Central Appetite Regulation | Directly accesses brainstem, septal nucleus, and hypothalamus through circumventricular organs |
| c-Fos Activation | Induces central c-Fos activation in 10 brain areas, including hindbrain areas directly targeted by semaglutide |
Key Advantage: Semaglutide is a highly specific GLP-1 receptor agonist with glucose-dependent action, reducing the risk of severe hypoglycemia in research models .
| Application | Research Focus | Status |
|---|---|---|
| Type 2 Diabetes | Glycemic control, insulin secretion, glucagon suppression | FDA-approved |
| Obesity Research | Appetite regulation, weight reduction, energy expenditure | Extensive research |
| Cardiovascular Research | Major adverse cardiovascular event (MACE) reduction in high-risk patients | FDA-approved |
| MASLD/MASH Research | Hepatic fat reduction, inflammation modulation, fibrosis | Active research |
| Metabolic Research | Insulin sensitivity, lipid metabolism, energy balance | Extensive research |
| Gastric Emptying | Gastrointestinal motility, satiety mechanisms | Active research |
| Parameter | Finding |
|---|---|
| Glycemic Control | Significantly reduces HbA1c in adults with type 2 diabetes |
| Weight Reduction (Oral) | High-dose oral semaglutide reduces weight by ~13% compared to placebo |
| Weight Reduction (Subcutaneous) | Reduces weight by ~10-12% compared to placebo |
| Lipidated Stability | Enhanced stability and half-life due to fatty acid modification |
| Half-Life | ~7 days (subcutaneous); ~1 week (oral with SNAC) |
| Cardiovascular Benefit | Reduces risk of major adverse cardiovascular events in high-risk patients |
| MASLD Improvement | Reduces hepatic fat and inflammation in preclinical models |
| Study | Year | Finding |
|---|---|---|
| SUSTAIN 1-7 Trials | 2017-2019 | Demonstrated superiority over placebo in glycemic control and weight reduction |
| SUSTAIN 6 Trial | 2016 | Once-weekly semaglutide (0.5 mg or 1 mg) reduced cardiovascular events in high-risk patients |
| PIONEER Trials | 2018-2019 | Oral semaglutide significantly reduces HbA1c and body weight dose-dependently |
| FLOW Trial | 2023 | Once-weekly semaglutide (1 mg) improved cardiovascular outcomes and reduced kidney adverse outcomes |
| JCI Insight Study | 2023 | Semaglutide directly accesses brainstem and hypothalamus; activates 10 brain areas involved in food intake |
| Liver Study | 2025 | Semaglutide modulates lipid pathways and reduces inflammation; lack of GLP-1 receptor in liver suggests indirect mechanisms |
| CagriSema Trial | 2022 | Semaglutide combined with cagrilintide achieved 89% time-in-range for glycemic control |
📖 Over 10 years of peer-reviewed research support Semaglutide research utility.
Add 1-2ml bacteriostatic water to the Semaglutide vial
Gently swirl – do not shake
Refrigerate at 2-8°C
Use within 30 days of reconstitution
| Parameter | Recommendation |
|---|---|
| Subcutaneous Research Dose | 0.25-2.4 mg once weekly |
| Oral Research Dose | 1.5-50 mg once daily |
| Frequency | Once weekly (SC) or once daily (oral) |
| Route | Subcutaneous injection or oral (research) |
| Half-Life | ~7 days (SC); ~1 week (oral) |
| Storage | Refrigerate after reconstitution |
| Aspect | Details |
|---|---|
| Boxed Warning | Risk of thyroid C-cell tumors (rodent studies); relevance to humans unknown |
| Contraindications | Personal/family history of MTC, MEN 2, hypersensitivity |
| Common Side Effects | Nausea, abdominal pain, diarrhea, decreased appetite, vomiting, constipation (>5%) |
| Serious Side Effects | Pancreatitis, diabetic retinopathy complications, hypoglycemia, acute kidney injury, hypersensitivity |
| Limitations | Not for type 1 diabetes; not studied in patients with pancreatitis history |
| Long-Term Data | Long-term cardiovascular safety established; long-term thyroid risk under investigation |
| Storage | Lyophilized: room temperature; Reconstituted: 2-8°C, use within 30 days |
| Advantage | Why It Matters |
|---|---|
| Lab-Verified >98% Purity | Third-party HPLC testing ensures quality and consistency |
| 5mg & 10mg Options | Flexible dosing for various research protocols |
| COA Included | Full transparency with every Semaglutide order |
| Fast Shipping | Orders processed within 24 hours |
| Discreet Packaging | Privacy guaranteed |
Semaglutide is supplied for research and laboratory use only. Not for human consumption. Not for therapeutic or diagnostic use. Use only by qualified researchers in controlled laboratory settings. Not FDA-approved for human use outside approved clinical protocols.
Always available!
Comes with each order!
Get access to expert resources.
Reviews
There are no reviews yet.